Look for pharmaceutical and biotech companies to make news this week as a UBS industry conference kicks off in New York. Also, Merrill Lynch analysts believe pricing power for prescription drugs is returning. What’s the trade?
Guy Adami likes Pfizer (PFE) because he feels it’s cheap right now.
Pete Najarian recommends Myraid Genetics (MYGN) as well as Quest Diagnostics (DGX) for preventative medicine.
Jeff Macke says Johnson & Johnson (JNJ) is a buy.
Got something to say? Send us an e-mail at email@example.com and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to firstname.lastname@example.org.
Trader disclosure: On Sept. 24, 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (DIS), (EMC), (ATVI); Najarian Owns (AAPL), (DGX), (VCLK); Najarian Owns (TSL) Options; Finerman's Firm Owns (JNJ), (NMX), (NYX), (VCLK), (TGT); Finerman's Firm Owns S&P 500 Puts; Finerman's Firm Owns Russell 2000 Puts; Finerman's Firm And Finerman Own (HD), (FLS); Finerman's Firm Owns (MSFT) Options